NASDAQ:TLSA Tiziana Life Sciences (TLSA) Stock Price, News & Analysis $1.54 -0.03 (-1.91%) As of 07/3/2025 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tiziana Life Sciences Stock (NASDAQ:TLSA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tiziana Life Sciences alerts:Sign Up Key Stats Today's Range$1.51▼$1.5650-Day Range$1.22▼$1.7852-Week Range$0.63▼$1.91Volume179,781 shsAverage Volume474,769 shsMarket Capitalization$179.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. Read More Tiziana Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks14th Percentile Overall ScoreTLSA MarketRank™: Tiziana Life Sciences scored higher than 14% of companies evaluated by MarketBeat, and ranked 2620th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Tiziana Life Sciences. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioTiziana Life Sciences has a P/B Ratio of 38.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tiziana Life Sciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.95% of the float of Tiziana Life Sciences has been sold short.Short Interest Ratio / Days to CoverTiziana Life Sciences has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tiziana Life Sciences has recently decreased by 16.68%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTiziana Life Sciences does not currently pay a dividend.Dividend GrowthTiziana Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.95% of the float of Tiziana Life Sciences has been sold short.Short Interest Ratio / Days to CoverTiziana Life Sciences has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tiziana Life Sciences has recently decreased by 16.68%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for TLSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows1 people have added Tiziana Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tiziana Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders39.82% of the stock of Tiziana Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Tiziana Life Sciences' insider trading history. Receive TLSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address TLSA Stock News HeadlinesTiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis TargetingJune 13, 2025 | seekingalpha.comTiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosingJune 13, 2025 | proactiveinvestors.comHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing to invest in new "E.I." Tech, which one expert estimates will grow by 200,000%. Becoming bigger than the automobile, PC, and cell phone markets... COMBINED!July 4 at 2:00 AM | Behind the Markets (Ad)Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis CenterJune 13, 2025 | globenewswire.comTiziana Life Sciences to Present at the Bio International ConventionJune 13, 2025 | globenewswire.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s DiseaseMay 23, 2025 | finance.yahoo.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's DiseaseMay 23, 2025 | globenewswire.comJournal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's DiseaseMay 15, 2025 | finance.yahoo.comSee More Headlines TLSA Stock Analysis - Frequently Asked Questions How have TLSA shares performed this year? Tiziana Life Sciences' stock was trading at $0.6962 at the start of the year. Since then, TLSA shares have increased by 121.2% and is now trading at $1.54. When did Tiziana Life Sciences IPO? Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering on the week of November 19th 2018. The company issued 1,000,000 shares at $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO. How do I buy shares of Tiziana Life Sciences? Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include NIO (NIO), Advanced Micro Devices (AMD), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), Inovio Pharmaceuticals (INO) and Pfizer (PFE). Company Calendar Today7/04/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TLSA CIK1723069 Webwww.tizianalifesciences.com Phone44-20-7495-2379FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.02 Quick Ratio1.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book38.50Miscellaneous Outstanding Shares116,850,000Free Float70,319,000Market Cap$179.95 million OptionableOptionable Beta-0.05 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:TLSA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.